Fluidigm and Qiagen's SABiosciences Team up to Provide Over 100 PCR Gene Expression Panels for Biomark Systems
News Mar 25, 2010
These kits are named the RT² Profiler™ PCR Arrays for the Fluidigm BioMark system.
These gene expression assays are specifically designed for the workflow of Fluidigm’s integrated fluidic circuits (IFCs) and the BioMark system. Each reagent kit includes pre-aliquoted reagents and primers needed for synthesizing first-strand cDNA ready for preamplification and pathway-focused analysis. PCR Arrays contain enough reagent to run five 96.96 Dynamic Array chips (customized panels are also available). PCR arrays come in a 96-well format making either 96.96 or 48.48 Dynamic Array™ chip set up fast, simple and affordable.
“SABiosciences solutions focusing on the analysis of pathways with real time assay panel kits are an excellent fit to our products. The kits include 96 cataloged gene expression assays, targeting genes in signal transduction, biological process, and disease-related pathways. The kits can provide a great solution for customers looking to lower start up costs, or that need pre-validated pathways for a new project,” said Mike Lee, Fluidigm’s Senior Director of Marketing.
“SABiosciences offers real-time PCR Arrays that are the most reliable and sensitive gene expression profiling technology for analyzing a focused panel of genes and now gain the additional benefits of Fluidigm’s genetic analysis technology,” said Shankar Sellappan, Ph.D., SABiosciences PCR Array Product Manager.
PCR arrays are increasingly being used in research on cancer, immunology, stem cells, toxicology, biomarker discovery and validation, and phenotypic analysis of cells and transgenic animals. For more information about RT² Profiler™ PCR Arrays for the Fluidigm BioMark System, please visit: http://sabiosciences.com/ArrayList.php.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.